Perspective Therapeutics Begins New Phase 1/2a Cohort for Targeted Melanoma Therapy

Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) has initiated a new cohort in its ongoing Phase 1/2a trial evaluating [212Pb]VMT01, a targeted alpha-particle therapy (TAT), in combination with nivolumab (Opdivo®) for patients with melanoma. This expansion follows encouraging early results from previous cohorts where [212Pb]VMT01, administered as a monotherapy, demonstrated a strong safety profile and early signs of anti-tumor activity. The trial focuses on patients with confirmed melanoma and positive MC1R imaging scans, aiming to assess the potential of combining radiopharmaceuticals with immune checkpoint inhibitors.

Company executives believe this novel approach could enhance both safety and efficacy in patients with limited treatment options. "The findings so far provide a strong foundation for further exploration of [212Pb]VMT01 in combination with immunotherapies," said Markus Puhlmann, Chief Medical Officer of Perspective. CEO Thijs Spoor added that this study will deepen the understanding of lower-dose radiopharmaceuticals in combination therapies, potentially leading to improved outcomes in advanced melanoma.